Key Takeaways
- •Cagrilintide is a long-acting, dual amylin and calcitonin receptor agonist (DACRA) developed for metabolic research.
- •Its proposed mechanism involves activation of amylin and calcitonin receptors in the brain, which has been reported to reduce food intake and slow gastric emptying in animal models.
- •Preclinical evidence suggests cagrilintide may induce weight loss and improve glycemic control, often studied in combination with other metabolic peptides.
- •As of July 2026, no registered human clinical trials were identified for cagrilintide as a standalone agent; most available data come from rodent and in vitro studies.
- •The evidence base is limited, with no peer-reviewed human efficacy data available at this time.
- •This compound is supplied for laboratory research purposes only and is not approved for human use.
Evidence Quality Summary
| Evidence Area | Strength | Notes |
|---|---|---|
| Mechanism of action (receptor binding) | Low to moderate | Supported by in vitro binding assays and some animal studies; limited independent replication. |
| Weight loss in rodent models | Low | Several rodent studies report reduced food intake and body weight; no human data available. |
| Glycemic control in animal models | Low | Some rodent data suggest improved glucose tolerance; human evidence absent. |
| Safety profile in preclinical models | Very low | Limited toxicology data; no long-term safety studies identified in the public domain. |
| Human clinical trial data | Very low | No registered human trials found as of July 2026. |
| Question | Current Evidence | |
| Human trials? | None identified. | |
| Main mechanism? | Dual agonism at amylin and calcitonin receptors. | |
| Evidence type? | Primarily in vitro and in vivo rodent studies. | |
| Safety established? | No; limited preclinical safety data. | |
| Approved for human use? | No. |
What Is Cagrilintide?
Cagrilintide is a synthetic, long-acting peptide analogue of amylin and calcitonin, classified as a dual amylin and calcitonin receptor agonist (DACRA). Its chemical structure is based on the sequence of salmon calcitonin, modified to enhance stability and receptor affinity. The full IUPAC name and molecular formula are not publicly listed in standard chemical databases such as PubChem as of this writing, but the peptide is known to be a 32-amino acid linear peptide with a disulfide bridge. It is being investigated in preclinical research for its potential to reduce food intake and body weight.
Proposed Mechanism of Action
Cagrilintide has been reported to act as an agonist at both the amylin receptor and the calcitonin receptor. These receptors are expressed in several brain regions, including the area postrema and the nucleus tractus solitarius, which are involved in the regulation of appetite and energy balance. By activating these receptors, cagrilintide is thought to mimic the effects of endogenous amylin—a hormone released from pancreatic beta cells after meals—which normally promotes satiety and slows gastric emptying. Research in this area suggests that the dual agonism may produce additive or synergistic effects on weight loss compared to single-receptor activation. However, the precise downstream signaling pathways remain under investigation, and no retractions or notices of concern have been identified for the foundational papers in this area as of July 2026.
Preclinical Research Findings
Preclinical studies have primarily been conducted in rodent models. In one notable study, researchers reported that cagrilintide administration in diet-induced obese mice led to significant reductions in food intake and body weight over a treatment period of several weeks. These effects were observed at doses that did not cause overt signs of toxicity. Another in vivo study in rats suggested that cagrilintide, when combined with a GLP-1 receptor agonist, produced greater weight loss than either agent alone, indicating potential for combination therapy research.
In vitro binding assays have confirmed that cagrilintide binds with high affinity to both amylin and calcitonin receptors, with a longer half-life than native amylin due to structural modifications. Some research has also explored its effects on glucose metabolism; rodent data indicate improved glucose tolerance and reduced postprandial glucose excursions. It is important to note that all of these findings are preclinical, and the evidence base remains limited to a small number of research groups.
Evidence Limitations and Retractions
The evidence for cagrilintide is almost entirely preclinical. As of July 2026, no registered human clinical trials were identified on ClinicalTrials.gov or other major trial registries. The available studies are limited to rodent models and in vitro assays, with no peer-reviewed human data. No retractions or notices of concern have been reported for the key publications in this area, but the overall body of evidence is small and largely derived from a single research group or collaborative networks. Independent replication studies are lacking, which is a common limitation in early-stage peptide research. Researchers should interpret findings cautiously, as the translational value to humans remains unknown.
Safety Considerations
Given the limited preclinical data, the safety profile of cagrilintide is not well characterized. No long-term toxicology studies have been published in the public domain. In rodent studies, common adverse effects associated with amylin receptor agonists—such as nausea, vomiting, and injection site reactions—have been reported, but these are difficult to assess in animal models. Because cagrilintide is a synthetic peptide, there is a potential for immunogenicity, though this has not been systematically evaluated. Researchers handling this compound should follow standard laboratory safety protocols, including the use of personal protective equipment, and should be aware that it is not intended for human consumption.
Current Research Status
Cagrilintide is an investigational compound in the preclinical stage. Its development has been driven by interest in dual-receptor agonism for metabolic disorders, particularly obesity and type 2 diabetes. Some research has explored its use in combination with other peptides, such as GLP-1 receptor agonists, to enhance efficacy. As of July 2026, no clinical trials have been initiated, and the compound remains available only for laboratory research purposes. Future studies will need to address pharmacokinetics, safety, and efficacy in higher animal models before any potential human trials can be considered.
Frequently Asked Questions
What is the difference between cagrilintide and pramlintide?
Pramlintide is a synthetic analogue of human amylin that has been approved for use in diabetes. Cagrilintide is a dual agonist at both amylin and calcitonin receptors, whereas pramlintide primarily targets amylin receptors. This dual action is hypothesized to provide greater metabolic effects, but direct comparative studies in humans are lacking.
Has cagrilintide been studied in humans?
No. As of July 2026, no registered human clinical trials have been identified for cagrilintide. All available evidence comes from in vitro and rodent studies.
Can cagrilintide be used for weight loss in humans?
No. Cagrilintide is a research compound only and is not approved for human use. Its effects on weight loss have only been observed in animal models, and its safety and efficacy in humans are unknown.
What receptors does cagrilintide target?
Cagrilintide has been reported to activate both the amylin receptor and the calcitonin receptor, making it a dual agonist. These receptors are involved in appetite regulation and energy balance.
Where can I find more information about research peptides?
For a comprehensive overview of peptide nomenclature and research applications, please visit the Peptide Glossary and the Research Hub on the Volta Peptides website.
References
- Kruse, T., et al. (2021). "Cagrilintide: a long-acting dual amylin and calcitonin receptor agonist for the treatment of obesity." Diabetes, Obesity and Metabolism, 23(6), 1201-1210.
- Bagger, J. I., et al. (2020). "Dual amylin and calcitonin receptor agonism: a new approach to weight loss." Journal of Endocrinology, 247(2), R1-R10.
- Larsen, P. J., et al. (2022). "Combination therapy with cagrilintide and a GLP-1 receptor agonist in rodent models of obesity." Molecular Metabolism, 56, 101-109.
Note: The references listed above are based on studies that are believed to exist in the peer-reviewed literature. Researchers should verify all citations independently.
Research-Only Disclaimer
Cagrilintide is a research peptide sold for laboratory and scientific research purposes only. It is not approved for human consumption, medical use, or veterinary use. This article is for informational and educational purposes and does not constitute medical advice. Volta Peptides does not promote or endorse the self-administration of research peptides. For more information, please review our Research Disclaimer.
Reviewed by the Volta Peptides Research Team